COVID-19 : Melatonin as a potential adjuvant treatment
Copyright © 2020. Published by Elsevier Inc..
This article summarizes the likely benefits of melatonin in the attenuation of COVID-19 based on its putative pathogenesis. The recent outbreak of COVID-19 has become a pandemic with tens of thousands of infected patients. Based on clinical features, pathology, the pathogenesis of acute respiratory disorder induced by either highly homogenous coronaviruses or other pathogens, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response very likely contribute to COVID-19 pathology. This leads to a cytokine storm and subsequent progression to acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and often death. Melatonin, a well-known anti-inflammatory and anti-oxidative molecule, is protective against ALI/ARDS caused by viral and other pathogens. Melatonin is effective in critical care patients by reducing vessel permeability, anxiety, sedation use, and improving sleeping quality, which might also be beneficial for better clinical outcomes for COVID-19 patients. Notably, melatonin has a high safety profile. There is significant data showing that melatonin limits virus-related diseases and would also likely be beneficial in COVID-19 patients. Additional experiments and clinical studies are required to confirm this speculation.
| Errataetall: |
CommentIn: Life Sci. 2020 Jul 15;253:117716. - PMID 32334009 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:250 |
|---|---|
| Enthalten in: |
Life sciences - 250(2020) vom: 01. Juni, Seite 117583 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Rui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvants, Immunologic |
|---|
| Anmerkungen: |
Date Completed 23.04.2020 Date Revised 07.12.2022 published: Print-Electronic CommentIn: Life Sci. 2020 Jul 15;253:117716. - PMID 32334009 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.lfs.2020.117583 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308029534 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308029534 | ||
| 003 | DE-627 | ||
| 005 | 20231225130848.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lfs.2020.117583 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1026.xml |
| 035 | |a (DE-627)NLM308029534 | ||
| 035 | |a (NLM)32217117 | ||
| 035 | |a (PII)S0024-3205(20)30331-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Rui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 |b Melatonin as a potential adjuvant treatment |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.04.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Life Sci. 2020 Jul 15;253:117716. - PMID 32334009 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier Inc. | ||
| 520 | |a This article summarizes the likely benefits of melatonin in the attenuation of COVID-19 based on its putative pathogenesis. The recent outbreak of COVID-19 has become a pandemic with tens of thousands of infected patients. Based on clinical features, pathology, the pathogenesis of acute respiratory disorder induced by either highly homogenous coronaviruses or other pathogens, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response very likely contribute to COVID-19 pathology. This leads to a cytokine storm and subsequent progression to acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and often death. Melatonin, a well-known anti-inflammatory and anti-oxidative molecule, is protective against ALI/ARDS caused by viral and other pathogens. Melatonin is effective in critical care patients by reducing vessel permeability, anxiety, sedation use, and improving sleeping quality, which might also be beneficial for better clinical outcomes for COVID-19 patients. Notably, melatonin has a high safety profile. There is significant data showing that melatonin limits virus-related diseases and would also likely be beneficial in COVID-19 patients. Additional experiments and clinical studies are required to confirm this speculation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a Immunomodulation | |
| 650 | 4 | |a Melatonin | |
| 650 | 4 | |a Oxidation-reduction | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Melatonin |2 NLM | |
| 650 | 7 | |a JL5DK93RCL |2 NLM | |
| 700 | 1 | |a Wang, Xuebin |e verfasserin |4 aut | |
| 700 | 1 | |a Ni, Leng |e verfasserin |4 aut | |
| 700 | 1 | |a Di, Xiao |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Baitao |e verfasserin |4 aut | |
| 700 | 1 | |a Niu, Shuai |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Changwei |e verfasserin |4 aut | |
| 700 | 1 | |a Reiter, Russel J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Life sciences |d 1965 |g 250(2020) vom: 01. Juni, Seite 117583 |w (DE-627)NLM000007579 |x 1879-0631 |7 nnns |
| 773 | 1 | 8 | |g volume:250 |g year:2020 |g day:01 |g month:06 |g pages:117583 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lfs.2020.117583 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 250 |j 2020 |b 01 |c 06 |h 117583 | ||